This article originally appeared on on Sept. 13, 2019.
The CRISPR-Chip garnered much attention earlier this year when the novel graphene-based biosensor CRISPR-Cas technology was introduced in a Nature Biomedical Engineering publication in March. This week, the two companies that have been straddling the technology that is able to detect a specific genetic mutation from a sample without the need for amplification or sequencing announced that they have merged. In addition, they have revealed an early access launch of their CRISPR-chip based product—Genome Sensor. We sat down with the founders of the companies at the AGBT precision health meeting in La Jolla, California, to learn more about how the CRISPR-chip came to be and their future goals.
The story of how the CRISPR-Chip evolved is from the outside, “a little bit messy” according to CEO Michael Heltzen. But, on the inside, he notes, it is “very logical.”
To read the entire story, visit .